Electronic Church

Reducing the risk of Post-PCI bleeding through medication

When the percutaneous coronary intervention or PCI is done in the angioplasty, there is the placing of stent in the coronary vessels. Hence, there is the introduction of the medications which is used for the diluting the blood and in this way, the platelets will not allow to aggregate the blood around the stent. In this way, the blood not clot and the affected artery will remain patent. On the other hand, finding out the great way to control the bleeding in these patients is one of the best ways that is thought of working for the great terms. Hence, there is also one complication that is being reported by the use of this medication. It is the bleeding which occurs at the site of stent, and the major reason which is accounted for it to happen is the presence of the anti coagulant therapy that has been done.

On the other hand, the use of the Bivalirudin has been thought and put to trial for checking out how much it will prevent for having the bleeding. The results are great, and the patients in which PCI has been done, the use of this medication had some of the great results. According to Circulation: Cardiovascular Interventions, the analysis on 8000 patients was done, and the results which were yielded on these patients were great as there was very less bleeding reported in these patients. Hence, using of this drug has been reported to have the amazing outcomes, and with all the great working put forward for it, NYU School of Medicine also decided to use this medicine on the cohort group and the results were quite amazing. The reason for being so much cautious about the bleeding in the Post-PCI patients is that there is the increased risk of death in these patients.

According to the HORIZONS-AMI trial, the combination of Bivalirudin and the heparin are producing the great results in the patients who are working for the best of it. On the other hand, many of South Asian countries have not proven it quite yielding for the reason that there are modifiable risk factors present. On the other hand, when the survival rates of the patients who are using this medicine is checked, it is 45% more in the patients who are not using it. Hence, the duration of this is making the good fractions for the patients who are going to use it for the good analysis.